Your browser doesn't support javascript.
loading
Obesity in Adolescents: A Review.
Kelly, Aaron S; Armstrong, Sarah C; Michalsky, Marc P; Fox, Claudia K.
Afiliação
  • Kelly AS; Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis.
  • Armstrong SC; Department of Pediatrics, Department of Population Health Sciences, Duke University, Durham, North Carolina.
  • Michalsky MP; Duke Clinical Research Institute, Duke Center for Childhood Obesity Research, Durham, North Carolina.
  • Fox CK; Department of Pediatric Surgery, Nationwide Children's Hospital and The Ohio State University, College of Medicine, Columbus.
JAMA ; 332(9): 738-748, 2024 09 03.
Article em En | MEDLINE | ID: mdl-39102244
ABSTRACT
Importance Obesity affects approximately 21% of US adolescents and is associated with insulin resistance, hypertension, dyslipidemia, sleep disorders, depression, and musculoskeletal problems. Obesity during adolescence has also been associated with an increased risk of mortality from cardiovascular disease and type 2 diabetes in adulthood. Observations Obesity in adolescents aged 12 to younger than 18 years is commonly defined as a body mass index (BMI) at the 95th or greater age- and sex-adjusted percentile. Comprehensive treatment in adolescents includes lifestyle modification therapy, pharmacotherapy, and metabolic and bariatric surgery. Lifestyle modification therapy, which includes dietary, physical activity, and behavioral counseling, is first-line treatment; as monotherapy, lifestyle modification requires more than 26 contact hours over 1 year to elicit approximately 3% mean BMI reduction. Newer antiobesity medications, such as liraglutide, semaglutide, and phentermine/topiramate, in combination with lifestyle modification therapy, can reduce mean BMI by approximately 5% to 17% at 1 year of treatment. Adverse effects vary, but severe adverse events from these newer antiobesity medications are rare. Surgery (Roux-en-Y gastric bypass and vertical sleeve gastrectomy) for severe adolescent obesity (BMI ≥120% of the 95th percentile) reduces mean BMI by approximately 30% at 1 year. Minor and major perioperative complications, such as reoperation and hospital readmission for dehydration, are experienced by approximately 15% and 8% of patients, respectively. Determining the long-term durability of all obesity treatments warrants future research. Conclusions and Relevance The prevalence of adolescent obesity is approximately 21% in the US. Treatment options for adolescents with obesity include lifestyle modification therapy, pharmacotherapy, and metabolic and bariatric surgery. Intensive lifestyle modification therapy reduces BMI by approximately 3% while pharmacotherapy added to lifestyle modification therapy can attain BMI reductions ranging from 5% to 17%. Surgery is the most effective intervention for adolescents with severe obesity and has been shown to achieve BMI reduction of approximately 30%.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Comportamental / Fármacos Antiobesidade / Cirurgia Bariátrica / Obesidade Infantil Limite: Adolescent / Child / Humans País/Região como assunto: America do norte Idioma: En Revista: JAMA Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Comportamental / Fármacos Antiobesidade / Cirurgia Bariátrica / Obesidade Infantil Limite: Adolescent / Child / Humans País/Região como assunto: America do norte Idioma: En Revista: JAMA Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos